Daiichi Sankyo anticoagulant gets nod in UK; GSK's Breo approved for Canada;

@FiercePharma: $GSK rehires former China government affairs director Shi. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: ICYMI: #FDA may add Baxter #saline Mexico plant to US supply. Now if Baxter can just quit having to recall saline. More | Follow @EricPFierce

@CarlyHFierce: What was summer before I covered takeover battles? | Follow @CarlyHFierce

> Daiichi Sankyo's new blood thinner Lixiana has been recommended for a second indication in England to prevent stroke and systemic embolism in adults with non-valvular atrial fibrillation. Story

> Taro Pharmaceuticals ($TARO) reported increased revenues for the second quarter. Release

> GlaxoSmithKline ($GSK) and Theravance ($THRX) on Thursday announced the approval in Canada of Breo Ellipta for the once-daily maintenance treatment of asthma in patients aged 18 years and older with reversible obstructive airways disease. Release

Medical Device News

@FierceMedDev: Updated w/ info from $MDT: Medtronic recalls CoreValve TAVR component due to presence of particulate matter. Story | Follow @FierceMedDev

@VarunSaxena2: FDA issues warning on heart pump safety issues: strokes, blood clots and bleeding. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: British watchdog cracks down on Pfizer for huge price hikes on epilepsy drug. Story | Follow @EmilyWFierce

> TAVR maker JenaValve receives $26.5M to fund U.S. studies. Report

> DexCom ups 2015 guidance but doesn't aim for profit; plans next-gen launches this year, in 2017. Story

> Cardinal scores $1B DOD contract as dealmaking delivers growth. Article

Biotech News

@FierceBiotech: Pfizer takes the lead in another hot immuno-oncology contest. Report | Follow @FierceBiotech

@JohnCFierce: Tick tock--Fierce 15 noms deadline is approaching. More | Follow @JohnCFierce

@DamianFierce: Probably the best thing about having lots of money is how it turns itself into even more money. Story | Follow @DamianFierce

> Decimated by clinical failure, Xoma turns to plan B. More

> NantKwest's record-setting IPO heaps another billion on Soon-Shiong's fortune. Story

> Sanofi deepens its Evotec ties with a $330M diabetes deal. Article